Repositorio de producción científica de la Universidad de Sevilla

Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain

 

Advanced Search
 
Opened Access Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain
Cites

Show item statistics
Icon
Export to
Author: Salavert, Miguel
Pascual Hernández, Álvaro
Cobo, Javier
Aragón, Belén
Maratia, Stefano
Aceituno, Susana
Grau, Santiago
Department: Universidad de Sevilla. Departamento de Microbiología
Date: 2018
Published in: Advances in Therapy, 35 (11), 1920-1934.
Document type: Article
Abstract: Introduction Clostridium difficile infection (CDI) is the major cause of infectious nosocomial diarrhoea and is associated with considerable morbidity, mortality and economic impact. Bezlotoxumab administered in combination with standard of care (S...
[See more]
Cite: Salavert, M., Pascual Hernández, Á., Cobo, J., Aragón, B., Maratia, S., Aceituno, S. y Grau, S. (2018). Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain. Advances in Therapy, 35 (11), 1920-1934.
Size: 1.489Mb
Format: PDF

URI: https://hdl.handle.net/11441/80741

DOI: 10.1007/s12325-018-0813-y

See editor´s version

This work is under a Creative Commons License: 
Attribution-NonCommercial-NoDerivatives 4.0 Internacional

This item appears in the following Collection(s)